Juno is a clinical-stage cell immunotherapy company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.


Updates from The Motley Fool

Latest updates on Juno Therapeutics from Fool.com.  The Fool has written over 100 articles on Juno Therapeutics.
3 Top Biotech Stocks for 2018

Celgene Corp., Juno Therapeutics, and Cara Therapeutics are three biotech stocks to watch in 2018.



Stock Performance

View Interactive JUNO Charts
Sponsored by

Key Data Points

Primary metrics and data points about Juno Therapeutics.
Current Price: $0.00
Prev Close: $0.00
Open: $0.00
Bid: $0.00
Ask: $0.00
Day's Range: $0.00 - $0.00
52wk Range: $0.00 - $0.00
Volume: 0
Avg Vol 0
Market Cap: $0
P/E (ttm): 0.00
EPS (ttm): ($4.10)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Juno Therapeutics.
CAPS Rating 5 out of 5
 
117 Outperform
3 Underperform
CAPS All Stars
 
30 Outperform
2 Underperform

How do you think Juno Therapeutics will perform against the market?



You pick for Juno Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Hans Bishop, CEO

90% Approve

Based on 31 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Juno Therapeutics.

Juno is a clinical-stage cell immunotherapy company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.

  • Exchange: NASDAQ